These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Meta-analysis of the association between angiotension-converting enzyme I/D polymorphism and susceptibility to children with Henoch-Schönlein purpura or Henoch-Schölein purpura nephritis].
    Author: Li H, Zhao D, Yang Q.
    Journal: Zhonghua Yi Xue Za Zhi; 2014 Jul 08; 94(26):2039-44. PubMed ID: 25312666.
    Abstract:
    OBJECTIVE: To explore the relationship between angiotension-converting enzyme (ACE) I/D polymorphism and susceptibility to Henoch-Schönlein purpura or Henoch-Schönlein purpura nephritis (HSP/HSPN) especially among Chinese children. METHODS: The publications up to December 31, 2013 from PubMed, Embase, Google Scholar, Springer Link, Highwire, Cochrane, ISI, CNKI and Wanfang databases were searched for relevant literature on the association between ACE I/D polymorphism and pediatric HSP/HSPN. Heterogeneity was evaluated. And Stata 12.0 was used to assess the association strength in terms of odds ratio (OR) and 95% CI. RESULTS: A total of 11 case-control studies fulfilled the inclusion criteria. And 5 articles were indentified for analyzing the relationship between ACE I/D polymorphism and pediatric HSP risk, involving 512 cases and 631 controls.Significantly risks of HSP were found (D/I: OR (95% CI) = 1.23 (1.04-1.46), P < 0.05; DD/DI + II:OR (95% CI) = 1.24 (0.77-2.00), P > 0.05 and II/DD+DI: 0.68 (0.52-0.90), P < 0.05). Nine articles were indentified for analyzing the relationship between ACE I/D polymorphism and pediatric HSPN risk, involving 446 cases and 877 controls.Significant risks of pediatric HSPN were found (D/I: OR (95% CI) = 1.52 (1.14-2.04), P < 0.05; DD/DI+II: OR(95% CI) = 1.85 (1.06-3.21), P < 0.05; II/DD+DI: OR(95%CI) = 0.62 (0.47-0.82), P < 0.05). CONCLUSIONS: In different ethnic groups, genotype DD of ACE I/D may increase the risk of pediatric HSP/HSPN and thus constitute a risk factor. Genotype II of ACE I/D may decrease the risks of pediatric HSP/HSPN and it may be a constitutively protective factor for pediatric HSP/HSPN.
    [Abstract] [Full Text] [Related] [New Search]